Ben Holland, Co-founder and CTO of Antiverse, said: “This agreement further validates our AI-driven drug discovery platform, successfully generating a panel of anti-PD-1 antibodies, with at least two potential candidates entering preclinical development. Through these innovative collaborations, Antiverse strives to accelerate the identification and development of novel antibody therapeutics for cancer, reducing drug discovery timelines and costs. We aim to continue to ‘open up’ the druggable antibody space.”
